Tirzepatide
41 articles on Tirzepatide, written by Shotlee and medically reviewed for clinical accuracy.
Mounjaro (Tirzepatide) PBS Listing Fails: Impact on Australian Patients
Eli Lilly Australia has announced that Mounjaro (tirzepatide) will not be listed on the Pharmaceutical Benefits Scheme (PBS) for Type 2 Diabetes, citing unsustainable funding conditions. This decision highlights ongoing challenges in accessing modern GLP-1 and GIP therapies.
6 min read
Inside India's GLP-1 Rush: Generics, Hype, Risks
In India, the GLP-1 rush is on—patients demand Ozempic or Mounjaro by name, generics slash costs to ₹1,290/month, fueled by Instagram and forums. But endocrinologists caution against indiscriminate use amid nausea, rebound weight, and serious risks. Inside the hype reshaping obesity treatment.
5 min read
Popular Weight Loss Drugs May Cause Hidden Muscle Loss, Study Finds
Popular drugs like semaglutide and tirzepatide are transforming weight loss for type 2 diabetes and obesity patients. But a new UNC study warns of hidden muscle loss that could impact strength and mobility. Here's what the research means for safe, healthy weight management.
5 min read
Social Media Reveals GLP-1 Side Effects Missed in Clinical Trials
Social media is spotlighting GLP-1 receptor agonist side effects that clinical trials overlooked, according to a new study in Nature Health. Researchers sifted through 410,198 Reddit posts on semaglutide and tirzepatide, finding 43.5% of users reporting issues like nausea and fatigue. These insights reveal patient concerns beyond traditional data.
4 min read
Tirzepatide Lowers Blood Sugar and Weight Faster in Type 2 Diabetes Study
A groundbreaking study reveals tirzepatide outperforms semaglutide and insulin degludec in speeding up blood sugar control and weight loss for type 2 diabetes patients. Participants on tirzepatide hit HbA1c targets below 7% in just eight weeks, compared to twelve weeks for alternatives. These faster results could boost long-term adherence and health outcomes.
4 min read
New Study: Why Ozempic Works Better for Some Due to Genetics
Ozempic and similar weight-loss drugs like tirzepatide work better for some patients due to specific genetic variants affecting GLP-1 and GIP receptors, a new 23andMe study shows. While average users lose 10% body weight, those with certain gene copies shed up to 1.5kg more—or face higher nausea and vomiting risks. This research uncovers why responses vary widely.
5 min read
Rosie O'Donnell's Mounjaro Face: Stark Side-by-Side Pics Exposed
Rosie O'Donnell, who started Mounjaro in January 2023 for diabetes management, has become a poster child for 'Mounjaro face' after shedding 10 pounds quickly. Side-by-side photos from September 2022 and October 2025 highlight sagging skin around her mouth and cheeks, with expert analysis noting a grayish hue. Despite cosmetic changes, she's embracing the weight loss benefits.
5 min read
What to Do When Tirzepatide Stops Working: Shift to Retatrutide
If Tirzepatide worked initially but now you've hit a plateau, it's not failure—it's metabolic adaptation signaling the next phase. California Trim Clinic is leading the shift to retatrutide, a triple-pathway therapy targeting energy expenditure for sustained results. Patients are moving beyond plateaus with physician-guided care.
4 min read
Lost 6 Stone on Mounjaro: Best Side Effect No One Talks About
Single mum Rebecca Tidy transformed her life by losing six stone on Mounjaro, but the real game-changer was the confidence boost that doubled her income. After ditching Saxenda due to side effects, Mounjaro helped her reclaim control. Here's her inspiring journey from exhaustion to empowerment.
7 min read
Ozempic Turned Happy Drunk to Sad One with Horrendous Hangovers
Trey Luker-Stewart lost 60 pounds on Ozempic, but it transformed his drinking from fun nights to anxious, emotional ones with brutal hangovers. As a Dallas bar owner, he's seen a 35% drop in alcohol sales linked to GLP-1 drugs. Doctors reveal why these medications blunt alcohol's rewards and worsen next-day effects.
5 min read
Eli Lilly Warns of Counterfeit Mounjaro, Zepbound Risks from Impurities
Eli Lilly, maker of Mounjaro and Zepbound, has discovered critical impurities in counterfeit tirzepatide versions mixed with vitamin B12. These compounded drugs pose unknown risks due to chemical reactions and lack of FDA oversight. With one in eight Americans using GLP-1s, experts urge sticking to approved medications.
5 min read
GLP-1 Persistence for Weight Loss Nearly Doubles in Recent Years
Persistence rates for GLP-1 medications like semaglutide and tirzepatide in patients without diabetes seeking weight loss have nearly doubled over the past five years, jumping from 33.2% in 2021 to 60.9% in mid-2024. New research highlights improved adherence, the role of drug switching, and factors like resolved supply shortages driving these gains. These trends offer hope for long-term obesity management.
5 min read
Healthier Happy Selects CoreAge Rx as Top Tirzepatide Online Destination
Independent health platform Healthier Happy has chosen CoreAge Rx as its preferred destination for tirzepatide online, highlighting its physician-supervised telehealth model, straightforward pricing, and direct-to-home delivery. This recognition underscores CoreAge Rx's role in simplifying access to GLP-1 therapies like tirzepatide and semaglutide for metabolic health.
5 min read
Amazon Pharmacy Adds Zepbound KwikPen to Same-Day Delivery
Amazon Pharmacy is streamlining GLP-1 access by adding Zepbound KwikPen to its same-day delivery service. This multi-dose device holds a full month's supply, addressing manufacturing bottlenecks and offering $299 cash-pay pricing—far below traditional $1,000 quotes. Integrated with Amazon One Medical, it provides personalized care for weight management and obstructive sleep apnea patients.
4 min read
Study: GLP-1 Drugs May Fight Addiction Across Major Substances
Patients on GLP-1 drugs like Ozempic report losing interest in cigarettes, alcohol, and more without effort. A physician-led study of over 600,000 VA patients reveals these medications cut addiction-related deaths by 50% and prevent new substance use disorders. This could transform treatment for alcohol, opioids, cocaine, cannabis, and nicotine.
5 min read
GLP-1s Curb Cravings Beyond Food: 600K Study Suggests
Patients on GLP-1 drugs report losing cravings not just for food, but for cigarettes, alcohol, and more—without effort. A new study of over 600,000 people confirms dramatic reductions in overdoses, deaths, and new addictions. Could semaglutide and tirzepatide redefine addiction care?
5 min read
GLP-1 Medications Like Ozempic May Cause Hair Loss: Here's Why
Social media is buzzing with reports of hair loss among GLP-1 users on drugs like Ozempic and Wegovy. While research is emerging, experts like Yale dermatologist Dr. Sara Perkins confirm patients are noticing more shedding. Here's the science behind it and steps to address it.
6 min read
Lilly Plans Broader Mounjaro Access in India Amid 100M Overweight
With nearly 100 million Indians overweight or obese, Eli Lilly is ramping up access to its game-changing drug Mounjaro across the country. President Winslow Tucker emphasizes responsible use under medical supervision amid rising demand for GLP-1 therapies. This move signals a shift in tackling obesity as a serious disease linked to heart complications.
6 min read
Novo Nordisk Stock Erases Wegovy Gains After CagriSema Miss
Novo Nordisk's stock has erased the last of its Wegovy-driven gains in a brutal week, down 21% after next-gen obesity drug CagriSema underperformed rivals. Despite 20.2% weight loss in trials, analysts downgrade amid patent cliffs and competition from Eli Lilly's tirzepatide. The company's pivot to oral Wegovy offers hope, but diversification pressures mount.
5 min read
UK Mounjaro Warning: Counterfeit Pens – Check Batch Numbers
The UK's MHRA has issued a critical warning about counterfeit Mounjaro pens following reports from Eli Lilly. These fake pens contain tirzepatide but may not be sterile, posing potential health risks. Patients are urged to verify batch numbers and report suspicions to the Yellow Card scheme.
5 min read
Tirzepatide Adverse Events: Subgroup Differences Explored
A new study in BMC Pharmacology and Toxicology uncovers critical subgroup differences in tirzepatide adverse events, showing higher GI intolerance in elderly patients and varied risks based on comorbidities. These insights highlight the need for tailored dosing in type 2 diabetes and obesity treatment. Understand how to balance benefits and risks effectively.
5 min read
GLP-1 Drugs May Treat Rare Genetic Obesity, Japanese Study Finds
A new Japanese study reveals that three popular GLP-1 drugs—semaglutide, tirzepatide, and retatrutide—may offer hope for rare genetic obesity linked to MC4R deficiency. In mice models, these drugs led to significant weight loss despite faulty hunger signals. Experts discuss the potential and limitations for human treatment.
5 min read
Tirzepatide Activates Brown Fat to Burn Calories, Mouse Study Shows
Tirzepatide doesn't just curb hunger—it may directly rev up fat-burning brown adipose tissue, according to a groundbreaking mouse study. Researchers separated its metabolic effects from simple calorie restriction, uncovering benefits for energy expenditure and blood glucose control. This could pave the way for more effective obesity therapies.
6 min read
Tirzepatide in Mounjaro Cuts Alcohol Intake Over 50%, Study Shows
The weight-loss drug Mounjaro's active ingredient, tirzepatide, is showing promise beyond metabolic health by slashing alcohol intake in animal models. A new study from the University of Gothenburg found it reduced voluntary consumption by over 50%, curbed binge drinking, and prevented relapse. This could signal a new avenue for treating alcohol use disorder through GLP-1/GIP receptor agonism.
6 min read
GP's Surprising Mounjaro Effects: Weight Loss and Mood Shifts After 3 Months
A 33-year-old GP tried Mounjaro for obesity and was stunned by more than just weight loss—his 'food noise' vanished, alcohol interest dropped, and mood stabilized. After shedding almost two stone in three months, urges returned upon stopping, highlighting obesity's chronic nature. Now back on 5mg, he emphasizes long-term strategies beyond medication.
5 min read
Study Finds Tirzepatide Cuts Alcohol Intake by More Than Half in Rodents
For the first time, researchers have demonstrated that tirzepatide—the key ingredient in Mounjaro—slashes voluntary alcohol consumption by more than half in rodents while curbing relapse-like drinking. Published in eBioMedicine, this University of Gothenburg study highlights effects on the brain's reward system, including dopamine modulation in the lateral septum. These findings build on prior semaglutide research and suggest potential for alcohol use disorder therapies.
6 min read
Eli Lilly Grabs Biggest Slice of GLP-1 Gold Rush Over Ozempic
Eli Lilly has overtaken Novo Nordisk in the GLP-1 gold rush, with Mounjaro and Zepbound now holding 60% of the U.S. market versus Ozempic and Wegovy's 39%. Backed by blockbuster revenue growth and superior weight loss results in head-to-head studies, Lilly's tirzepatide drugs are reshaping obesity and diabetes treatment. Investors and patients alike are taking notice of this shift.
5 min read
CoreAge Rx Tops GLP-1 Planet Review: 9.6/10 Rating, $99/Mo Pricing Out of 78
An independent review by GLP-1 Planet has crowned CoreAge Rx as the top GLP-1 provider out of 78 evaluated, with a standout 9.6/10 rating driven by its $99/month flat pricing. This includes virtual consultations, medications like semaglutide and tirzepatide, ongoing support, and direct delivery. Patients benefit from transparent, comprehensive weight management care.
5 min read
Soha Ali Khan Reacts to Aishwarya Mohanraj's Mounjaro Weight Loss Reveal
Comedian and influencer Aishwarya Mohanraj bravely shared that weekly Mounjaro injections helped her shed 22kg in just 6 months, from 74kg to 52kg, overcoming deep insecurities. Soha Ali Khan commended her candor, saying 'so finally someone said it' in an industry rife with simplified transformation tales. Learn the details and what Mounjaro means for weight loss.
5 min read
Mounjaro Sales Hit $7.4B as Regulators Ban Social Media Ads; Tirzepatide Link...
Eli Lilly reports Mounjaro sales skyrocketing to $7.4 billion in Q4 2026, driven by explosive GLP-1 demand. New 2026 research links tirzepatide to liver inflammation resolution and reduced heart failure risks. Meanwhile, UK regulators ban unauthorized social media promotions of these prescription drugs.
5 min read
Woman's 39-lb Breasts Won't Stop Growing: Gigantomastia Discovered on Mounjaro
A 30-year-old woman from East Anglia discovered her rare gigantomastia condition—causing her breasts to weigh 39 lbs.—while losing weight on Mounjaro. Despite rapid breast growth amid overall weight loss, she faces numb arms, scarring, and breathing issues. Her story highlights the unexpected challenges of GLP-1 medications like tirzepatide.
5 min read
Lost 7st on Mounjaro: Cold Side Effect Costs £70/Month
A Liverpool mum shed 7st on Mounjaro in under a year, transforming her life—but a freezing side effect dubbed 'MJ Freeze' has spiked her energy bills by £70 a month. Emilly Murray now layers up at home with heated blankets and gloves just to stay warm. Despite the chill, she says it's worth every penny for silencing food noise and boosting her health.
5 min read
Tirzepatide vs Semaglutide: Weight Loss Duration After Stopping
GLP-1 medications like semaglutide and tirzepatide deliver impressive weight loss, but what happens when you stop? Pivotal trials reveal significant regain risks, underscoring obesity as a chronic condition. This guide breaks down the evidence and offers practical insights for sustained results.
4 min read
Lost 11st on Mounjaro: Simple Trick Beat Plateau
Emilly Murray transformed from 22st 2lbs to a slim 9st using Mounjaro, conquering binge eating and food noise. After hitting a plateau at 11st, she boosted water intake to 2-3 liters daily and increased meat and fish consumption. This simple strategy reignited her weight loss toward her 10st goal.
3 min read
GLP-3s, Monthly Pens: Next Obesity Drugs Leap in 2026
GLP-1 drugs like Ozempic and Mounjaro have revolutionized weight loss, and the next wave—GLP-3s such as retatrutide—promises even greater results. Eli Lilly's phase 3 trial revealed up to 28.7% body weight loss in 48 weeks. Discover monthly injections, oral pills, and emerging indications for 2026.
3 min read
Mounjaro Helped Weight Loss But Caused Pancreatitis
A woman called Mounjaro 'magical' after dropping 3.5 stone and easing PCOS symptoms. But intense pain hospitalized her with pancreatitis linked to the drug. Now facing lifelong risks, she warns others to monitor symptoms closely.
3 min read
Mounjaro 'Magical' Until Pancreas Began Dying: Patient
Alisha Trafford called Mounjaro 'magical' after dropping 3.5 stone and easing PCOS symptoms. But intense pain led to hospitalizations for pancreatitis and pancreatic necrosis, linked by doctors to the drug. She warns others to monitor symptoms closely.
3 min read
GLP-1 Therapy: Benefits for Metabolic Health
GLP-1 medications extend beyond diabetes and weight loss to enhance overall metabolic health. They improve insulin sensitivity, curb chronic inflammation, and optimize cholesterol levels. Patients often report sustained energy and better wellness.
2 min read
Emilly's Mounjaro Journey: Beating Plateau for Lasting Loss
Emilly dropped from 22st to 9st 2lb on Mounjaro by tackling her plateau with more water and protein. Experts reveal why 85% of GLP-1 users stall and share proven strategies to restart progress. Avoid rapid regain by combining drugs with lifestyle changes.
3 min read
Woman Pays £200/Month for Life After Quitting Mounjaro
A woman who shed over four stone on Mounjaro regained weight rapidly after quitting due to overwhelming food noise. She returned to the drug at 5mg, committing to £200 monthly for life to sustain her size 12 figure. Her story highlights GLP-1 challenges in long-term weight management.
2 min read
What is the price of tirzepatide for shedding pounds with and without coverage?
Tirzepatide, known as Mounjaro or Zepbound, serves as a medication for diabetes and weight management but comes with a steep price. Without insurance, monthly expenses can range from $500 to $1,900, varying by type and purchase location. This piece explores pricing details, insurance coverage, cost-saving strategies, and budget-friendly substitutes.
8 min read